Regorafenib and Nivolumab Simultaneous Combination Therapy for Advanced and Metastatic Solid Tumors: Phase I Clinical Trial
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms REGONIVO
- 05 Jun 2018 According to trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology, first three patients were enrolled and treated in level 1 as of January 2018.
- 05 Jun 2018 Trial design was presented at 54th Annual Meeting of the American Society of Clinical Oncology.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.